Our research and discovery sites across China, Denmark, India, the United Kingdom and the United States are designed to provide the best scientific environment for the discovery and development of breakthrough medicines.
Across our global research and development network, we are working with both well established and cutting-edge research technology platforms that provide us with the techniques, methods and processes that enhance our treatment accuracy and search.
Below you can get to know our global R&D centres even better.
We were the first global pharmaceutical company to establish a research facility in China. Located in Zhongguancun Life Science Park in Beijing, our research centre in China is a technology centre of excellence and plays a key role in our discovery of novel drug candidates.
Our centre in Bangalore operates as an integrated part of the project-centric development organisation. The team delivers data management, biostatistics and programming, medical writing, publishing, safety surveillance and medical communication for clinical trials and marketed products.
Måløv is our largest research centre, a site for innovation, idea generation, protein and peptide engineering and formulation, and preclinical testing of medicine candidates across our therapy areas.
The site houses our early drug discovery laboratories, as well as facilities for production upscaling and formulation of lead medicine candidates for clinical testing.
One of our teams at the research centre in Bagsværd is responsible for developing, formulating and manufacturing drug candidates for pre-clinical and clinical testing.
Another team is involved in the collection of adverse events, safety surveillance and event adjudication related to clinical trials, as well as the handling of complaints and product recalls, when needed.
Our centre in Søborg is a project-centric workplace focused on late-stage development across all our therapy areas.
This includes conducting and reporting on clinical trials, registering products, sharing the science, and engaging with health authorities, professional associations and the medical community.
Our research centre in Hillerød is our device innovation hub and a key location for our long-standing industry leadership in pioneering new medical devices and delivery technologies.
With its location in the heart of the University of Oxford medical campus, our research centre and transformational research unit in Oxford brings industry and academia closely together.
The research is focused on discovering novel disruptive therapies for cardiometabolic diseases by combining deep disease understanding of human biology with big data.
The R&D Digital Hub in London serves as an essential centre for cultivating and attracting digital talents, while also fostering increased external collaborations with industry peers, leading tech companies, and startups within the vibrant London AI ecosystem.
Cambridge is the headquarters for Global R&D Business Development and External Innovation across all our therapeutic and technology areas. Containing functions in Business Development, Search & Evaluation, and Alliance Management, Cambridge houses the full complement of business functions needed for our external partnering activities. Having a physical presence in the one of the world’s largest life sciences ecosystems is part of our strategy to access the high level of innovation that the US has to offer.
In Cambridge, we work with local companies, venture capitalists, universities, and teaching hospitals to access technologies and therapeutic molecules that allow us to help patients in all our current therapeutic areas. Through a variety of partnership models, we use this innovation to help advance and expand its product portfolio.
In Lexington we are focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease.
Our proprietary GalXC™ and GalXC-Plus™ RNAi technologies have the potential to address conditions that are difficult or impossible to treat with other modalities. Also onsite in Lexington is the Boston Global Development team, which is responsible for leading the clinical advancement of GalXC™ and GalXC-Plus™ RNAi investigational therapies and select candidates from the broader Novo Nordisk portfolio, targeting both rare and prevalent diseases.
Our research centre located in Watertown is focused on the development and commercialisation of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.
The centre's R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. The centre's team is focused on activities supporting clinical supply chain, drug formulation & manufacturing, and GMP, GCP, auditing in support of Sickle Cell Disease (SCD) programs.
